The HSE has offered the HPV vaccine to all girls in first year in second level schools since 2010 to protect them from cervical cancer in adulthood. HPV vaccine is offered to this age group because the response to the vaccine is best at this age.
The vaccine is recommended to reduce the burden of cervical cancer for women by
- the World Health Organization
- the International Federation of Obstetricians and Gynecologists
- the National Immunisation Advisory Committee .
The HPV vaccine is available free of charge from the HSE for all girls in 1st year of second level school.
The vaccine is given through a school based programme, to ensure high vaccine uptake. However, in specific instances some girls will be invited to special HSE clinics for their vaccines.
The HSE will let you know the date the school immunisation team will attend your daughter’s school to give the HPV vaccine. If a student misses the vaccine in school, the HSE will arrange for the student to be vaccinated at a HSE clinic.
To read more about HPV please visit the following pages
The following information materials are available for parents of girls in 1st year of all second level schools and age equivalent in special schools or home schooled.
Information Booklet - English | Irish | Arabic | Simplified Chinese | German | French | Polish | Portuguese | Romanian | Russian
Consent Form - English and Irish combined form
Post Vaccination Advice - English | Irish
If you have any questions please contact the schools immunisation programme office in your area. The contact phone numbers are available in English and Irish.
More Information about HPV can be found at the following websites:
The following information materials are available for healthcare professionals who carry out the programme.
(Please note when you click on the SPC or PIL for Gardasil you will be leaving our website www.immunisation.ie)
The following information has been circulated to school principals and GPs
Medicine Protocol for the School Immunisation Programme
Gardasil safety reports
- The World Health Organization Global Advisory Committee for Vaccine Safety (GACVS) has reviewed the evidence on the safety of Gardasil vaccine. WHO concluded in December 2015 that Gardasil continues to have an excellent safety profile. Further information can be found here
- In November 2015 the European Medicines Agency (EMA) reported on a review of HPV vaccines. This report found no evidence the vaccine was linked to chronic fatigue like conditions. On January 12 2016 the EMA issued a final report on this review of HPV vaccines: “EMA confirms evidence does not support that they cause CRPS or POTS” Please see link for full details at http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/European_Commission_final_decision/WC500196773.pdf
- Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P and Hviid A (2013). Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 347:f5906 http://www.bmj.com/content/347/bmj.f5906
- Centers for Disease Control and Prevention (2016) Frequently Asked Questions about HPV Vaccine Safety http://www.cdc.gov/vaccinesafety/vaccines/hpv/hpv-safety-faqs.html
- Centers for Disease Control and Prevention (2014). Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007-2013, and Postlicensure Vaccine Safety Monitoring, 2006-2014 - United States. MMWR; 63 (29) 620-624 http://www.cdc.gov/mmwr/pdf/wk/mm6329.pdf
- International Federation of Gynecology and Obstetrics FIGO (2013). Statement on HPV Vaccination Safety, August 2nd, 2013 http://www.figo.org/search?cx=%27006260962696807358306%3Ack4j2ap-l1u&cof=FORID%3A11&ie=ISO-8859-1&query=figo+statement+on+hpv+vaccines
- World Health Organization (2013). Global Advisory Committee on Vaccine Safety. Update on human papillomavirus vaccines. Weekly Epidemiological Record 29 309-312 http://www.who.int/wer/2013/wer8829.pdf
- Irish Medicines Board (2011). Overview of national monitoring experience with Gardasil. http://www.hpra.ie/docs/default-source/Safety-Notices/imb_gardasil_webupdate_19jul2011.pdf
- Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J (2009). Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. Aug 19;302(7):750-7 http://jama.ama-assn.org/cgi/content/full/302/7/750
- Stillo M, Santisteve P & Lopalco P. ECDC (2015). Safety of human papillomavirus vaccines: a review, Expert Opin. Drug Saf. 14(5) P1-16 http://informahealthcare.com/doi/pdf/10.1517/14740338.2015.1013532
- World Health Organization (2014). Human papillomavirus vaccines: WHO position paper, Weekly epidemiological record position paper, No. 43, 89, 465-492 http://www.who.int/wer/2014/wer8943.pdf
- The following links can be used to access presentation slides from meetings held in May and August 2010 relating to HPV. Training slides from the HPV training programme held on the 6th May 2010.
- Copy of Prof Margaret Stanley’s presentation titled HPV VLP Vaccine Development and Impact. Prof Stanley spoke to an audience on 31st August 2010.
This page was updated on 19/08/2016